Emma Walmsley's Remuneration Jumps 50% to £15.6m in Final Year Leading GSK
GSK, Britain's second-largest pharmaceutical company, has disclosed that Emma Walmsley received a substantial pay increase of almost 50% in her final year as chief executive, with her total remuneration reaching £15.6 million for 2025. The bulk of this package, amounting to £10 million, came from share bonuses, reflecting a significant rise in the company's stock price during her tenure.
Breakdown of Walmsley's Pay Package
In 2025, Walmsley was paid a salary of £1.4 million, slightly higher than the previous year, while her annual bonus increased to £3.5 million, up from £2.9 million in 2024. The long-term incentive plan saw the vesting share price rise to £21.65, compared with £14.43 the year before, contributing to the hefty share bonus component. A spokesperson for GSK stated that this remuneration was justified by strong performance against stretching targets, including sales and profit growth, as well as securing five major new product approvals in the United States.
GSK's Financial Performance Under Walmsley
During Walmsley's leadership, which spanned from 2017 until she handed over to Luke Miels at the start of this year, GSK achieved notable financial milestones. The company's turnover increased by 7% to £32.7 billion in 2025, bolstered by revenue from treatments in areas such as cancer, HIV, and asthma. Pre-tax profit more than doubled to £7.4 billion in the same year. However, GSK anticipates a slowdown in sales growth for the current year.
Walmsley set an ambitious sales target of at least £40 billion by 2031, a goal reaffirmed by her successor, Luke Miels, in February. Miels has emphasized a strategy of scientific courage and agility to produce more competitive products in the pharmaceutical market.
Strategic Restructuring and Industry Context
Under Walmsley's guidance, GSK underwent its most significant corporate restructuring in two decades, which included the 2022 spinoff of its consumer healthcare arm into a separate entity named Haleon, featuring well-known brands like Sensodyne, Panadol, and Advil. Despite facing pressure from activist investor Elliott Management, Walmsley maintained her position and focused on increasing research and development spending, with a sharpened emphasis on respiratory, immunology, inflammation, cancer medicines, and vaccines.
In comparison, Pascal Soriot, the chief executive of rival AstraZeneca, the UK's largest pharmaceutical firm, received a 6.4% pay rise last year, bringing his total remuneration to £17.7 million. He is poised for a further increase to up to £19.6 million this year, potentially reclaiming the title of the UK's highest-paid chief executive.
Transition to New Leadership
Luke Miels, who succeeded Walmsley after serving as chief commercial officer and being recruited by her from AstraZeneca in 2017, has already made strategic moves since taking the helm on January 1. These include a £1.6 billion acquisition of a Californian biotech company developing a medication for severe food allergies. Miels will receive a lower base salary of £1.38 million but could earn a total remuneration package of up to £16.6 million, inclusive of long-term share bonuses, as he steers GSK toward its future goals.
